What is Balaxi Pharmaceuticals Ltd (BALAXI) share price return in the past 10 years?

Data is not available for this company

What is the share price of Balaxi Pharmaceuticals Ltd (BALAXI)?

Company share prices are keep on changing according to the market conditions. The current trading price of Balaxi Pharmaceuticals Ltd (BALAXI) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Balaxi Pharmaceuticals?

The latest standalone P/E ratio of Balaxi Pharmaceuticals as of 01-Jan-1970 is 26.08.

What is the P/B ratio of Balaxi Pharmaceuticals Ltd (BALAXI)?

The latest standalone P/B ratio of Balaxi Pharmaceuticals Ltd (BALAXI) as of 01-Jan-1970 is 1.01.

What is the 52-week high and low of Balaxi Pharmaceuticals Ltd (BALAXI)?

The 52-week high of Balaxi Pharmaceuticals Ltd (BALAXI) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Balaxi Pharmaceuticals Ltd (BALAXI) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Balaxi Pharmaceuticals Ltd (BALAXI)
Brand: Balaxi Pharmaceuticals

Balaxi Pharmaceuticals Ltd (BALAXI)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BALAXI Trading | Small Cap | Balaxi Pharma. Share Price

Balaxi Pharmaceuticals Ltd (BALAXI)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BALAXI Trading | Small Cap | Balaxi Pharma. Share Price

Key Metrics

Valuation Multiples

Market Cap

₹134 Cr.

Current Price

₹0

52-Week Low / High

₹0 / 0

TTM EPS

₹0.9

TTM Sales

₹80.9 Cr.

Book Value per Share

₹24.1

P/E Ratio

26.08

Lower than its 5-year historical median

Industry PE

35.7

Price to Book (P/B)

1.01

Lower than its 5-year historical median

Price to Sales (P/S)

1.66

Lower than its 5-year historical median

EV/EBITDA

15.56

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

2.93%

Outperforms industry median

Return on Capital Employed (ROCE)

5.12%

Outperforms industry median

Return on Assets (ROA)

2.19%

Operating Profit Margin

4.3%

Net Profit Margin

5.91%

Gross Profit Margin

9.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

-13.12%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-51.21%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-1.37%

Asset Quality

Promoter Holding

65.99%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹122 Cr.

Equity

₹11 Cr.

Face Value

₹2

All Time Low / High

- / -

Balaxi Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Not Good

Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Balaxi Pharmaceuticals Ltd a good quality company?

Balaxi Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Balaxi Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Balaxi Pharmaceuticals Ltd vs industry peers?

Balaxi Pharmaceuticals Ltd revenue CAGR is 5.97%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Balaxi Pharmaceuticals Ltd?

Promoters hold 65.99% of the Balaxi Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Balaxi Pharmaceuticals Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -47.31% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-2.1%	-4.7%	-39.7%	96.2%	58.4%	55.4%	37.1%	28.2%	6.1%	5.1%	-
Value Creation Index ⓘ	-1.2	-1.3	-3.8	5.9	3.2	3.0	1.7	1.0	-0.6	-0.6	-
Growth Parameters ⓘ
Sales ⓘ	0.1	0	0	13.6	45.6	86.9	101	108	70.2	61	81
Sales YoY Gr.	-	-100%	NA	NA	235.5%	90.4%	16.6%	6.8%	-35.1%	-13.1%	-
Adj EPS ⓘ	-0.1	-0.1	-0.5	1.3	1.2	2.8	2.6	2.4	0.5	0.3	0.9
YoY Gr.	-	NA	NA	NA	-8.3%	129.5%	-8.9%	-6.7%	-81.1%	-40%	-
BVPS (₹) ⓘ	2.1	1.5	1	2.3	5.6	8.7	11.6	16.1	21.6	23.2	24.1
Adj Net Profit ⓘ	-0.1	-0.2	-0.8	2	6.1	14	12.8	12.1	2.5	1.5	5
Cash Flow from Ops. ⓘ	-0	-0.1	-0.7	-1.5	-14.4	13.5	8.9	-7.1	-1.8	-7.6	-
Debt/CF from Ops. ⓘ	-5.8	0	0	0	0	0.3	0.2	-1.5	-7.6	-4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	120.3%	6%	-15.6%	-13.1%
Adj EPS ⓘ	NA	-26%	-52.7%	-40%
BVPSⓘ	30.8%	32.7%	26%	7.2%
Share Price	-	-47.6%	-64.2%	-55.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-2.5	-6.4	-39.6	79.7	38.6	39.2	25.2	16.2	2.3	1.2	3.9
Op. Profit Mgn % ⓘ	-145.1	0	0	12	19	21.9	17.1	15.6	7.7	4.3	0.9
Net Profit Mgn % ⓘ	-169.2	0	0	14.9	13.4	16.1	12.6	11.2	3.5	2.5	6.4
Debt to Equity ⓘ	0.1	0	0	0	0	0.1	0	0.1	0.1	0.2	0
Working Cap Days ⓘ	1,827	0	0	80	160	173	193	237	423	518	188
Cash Conv. Cycle ⓘ	-338	0	0	39	103	103	108	154	322	432	61

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0	0	0	14	46	87	101	108	70	61
Operating Expenses ⓘ +	0	0	1	12	37	68	84	91	65	58
Manufacturing Costs	0	0	0	0	0	0	0	0	0	0
Material Costs	0	0	0	10	33	63	77	82	56	51
Employee Cost	0	0	0	1	2	2	3	4	5	5
Other Costs ⓘ	0	0	1	1	2	3	4	5	3	3
Operating Profit ⓘ	-0	-0	-1	2	9	19	17	17	5	3
Operating Profit Margin (%)	-145.0%	-	-	11.5%	18.9%	21.9%	17.1%	15.6%	7.6%	4.3%
Other Income ⓘ +	0	0	0	1	1	2	3	7	2	5
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	0	0	0	1	2	2
Depreciation ⓘ	0	0	0	0	0	0	0	1	1	0
Profit Before Tax ⓘ	-0	-0	-1	2	9	21	20	22	6	5
Tax ⓘ	-0	0	0	0	3	5	5	6	2	2
Profit After Tax	-0	-0	-1	2	6	15	15	16	4	4
PAT Margin (%)	-169.0%	-	-	14.5%	14.2%	17.4%	14.5%	15.0%	5.2%	5.9%
Adjusted EPS (₹)	-0.1	-0.1	-0.5	1.3	1.3	3.0	2.9	3.2	0.7	0.7
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	3.40%	0%	0%	0%

Valuation of Balaxi Pharma. - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3	2	2	4	28	43	58	82	118	128
Share Capital ⓘ	3	3	3	3	10	10	10	10	11	11
Reserves ⓘ	0	-1	-1	0	18	33	48	72	107	117
Debt +	0	0	0	0	0	4	2	11	14	30
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	4	2	11	14	30
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0	2	7	17	16	17	12	9
Others Liabilities ⓘ	0	0	0	1	3	6	6	20	10	7
Total Liabilities ⓘ	4	2	2	6	38	69	82	130	154	174
Fixed Assets
Net Fixed Assets ⓘ +	0	0	0	0	0	1	2	8	7	7
Gross Block	0	0	0	0	0	1	3	9	8	7
Accumulated Depreciation	0	0	0	0	0	0	0	1	1	0
CWIP ⓘ	0	0	0	0	0	0	1	3	2	22
Investments ⓘ	3	0	0	0	0	20	20	20	20	25
Inventories	0	0	0	0	1	0	0	1	1	0
Trade Receivables	0	0	0	5	31	48	52	78	77	90
Cash Equivalents	0	2	2	0	4	0	1	18	44	29
Others Assets ⓘ	0	0	0	0	2	0	7	2	3	2
Total Assets ⓘ	4	2	2	6	38	69	82	130	154	174

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0	-0	-1	-2	-14	13	9	-7	-2	-8
PBT ⓘ	-0	-0	-1	2	9	21	20	22	6	5
Adjustment ⓘ	0	0	0	0	0	0	0	1	2	3
Changes in Working Capital ⓘ	0	0	0	-4	-23	-5	-5	-25	-4	-14
Tax Paid ⓘ	0	0	0	-0	-1	-2	-6	-5	-5	-2
Cash Flow From Investing Activity ⓘ +	0	3	-0	-0	-0	-20	-7	-2	0	-25
Capex	-0	0	-0	-0	-0	-1	-2	-0	0	-0
Net Investments	0	3	0	0	0	-19	-0	0	-0	-5
Others ⓘ	0	0	0	0	-0	0	-5	-2	1	-20
Cash Flow From Financing Activity ⓘ +	-0	-0	0	0	18	3	-2	26	28	17
Net Proceeds from Shares ⓘ	0	0	0	0	18	0	0	18	26	3
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	-0	0	0	0	-0	-0	-0	-1	-2
Dividend Paid ⓘ	-0	0	0	0	0	0	0	-0	0	0
Others ⓘ	0	-0	0	0	0	4	-2	9	3	16
Net Cash Flow ⓘ	-0	2	-1	-2	3	-3	0	17	26	-15

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-2.52	-6.37	-39.69	77.47	41.07	42.42	29	23.22	3.66	2.93
ROCE (%)	-2.11	-4.69	-39.69	96.22	58.38	55.42	37.14	28.22	6.08	5.12
Asset Turnover Ratio	0.01	0	0	3.49	2.07	1.63	1.34	1.02	0.49	0.37
PAT to CFO Conversion(x)	N/A	N/A	N/A	-1	-2.33	0.87	0.6	-0.44	-0.5	-2
Working Capital Days
Receivable Days	34.60	0	0	147	146.80	166.70	180.60	220.10	403.10	498.80
Inventory Days	0	0	0	0	6.70	1.80	0	5.10	6.10	2.50
Payable Days	0	0	0	38.80	50	67.90	76.90	73.40	96	76.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Balaxi Pharmaceuticals Ltd FAQs

The current trading price of Balaxi Pharma. on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Balaxi Pharma. stood at ₹134.2 Cr

The latest P/E ratio of Balaxi Pharma. as of 31-Dec-1969 is 26.08.

The latest P/B ratio of Balaxi Pharma. as of 31-Dec-1969 is 1.01.

The 52-week high of Balaxi Pharma. is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Balaxi Pharma. is ₹80.85 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Balaxi Pharmaceuticals Ltd is a below average quality company.

The key valuation ratios of Balaxi Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Balaxi Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Its markets extend across the continents of Americas, Africa and the Caribbean islands. It is a dynamic and responsible company, with a rich and growing portfolio of branded and generic medicines and consumer products.

Business area of the company

The company is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products

History and Milestones

2003-07

Commenced Pharmaceutcal business by supplying white labeled products to customers in Africa.
Sourcing was from WHO GMP certified plants based in India.

2008-10

Created frontend presence for its Pharmaceutical Business by setting up 1st wholesale depot in Angola in 2008.

2011-13

Started sourcing pharmaceutical from WHO GMP certified manufacturers in China by setting up an office in China in 2011.
Opened first wholesale depot for its ancillary business in Angola.

2014-16

In 2014, the group expanded its pharmaceutical business in Angola by setting up its 12th wholesale depot and a central distribution warehouse.
Made in-roads in Dominican Republic pharmaceutical market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse.

2017-19

Set-up central distribution warehouse in Guatemala marking the entry of Balaxi into its third geography.
Leveraged the vast on-ground infrastructure in Angola by entering branded consumer goods products business in 2019.

2020

Submitted several technical dossiers of Pharmaceutical products in EL Salvador and Honduras for product registrations.

Balaxi Pharmaceuticals Ltd (BALAXI)

Balaxi Pharmaceuticals Ltd (BALAXI)

Balaxi Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Balaxi Pharma. - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Balaxi Pharmaceuticals Ltd FAQs

About Balaxi Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Balaxi Pharmaceuticals Ltd (BALAXI)

Balaxi Pharmaceuticals Ltd (BALAXI)

Balaxi Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Balaxi Pharma. - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Balaxi Pharmaceuticals Ltd FAQs

What is the share price of Balaxi Pharma.?

What is the market cap of Balaxi Pharma.?

What is the P/E ratio of Balaxi Pharma.?

What is the P/B ratio of Balaxi Pharma.?

What is the 52-week high and low of Balaxi Pharma.?

What is the TTM revenue of Balaxi Pharma.?

Is Balaxi Pharmaceuticals Ltd a good quality company?

Is Balaxi Pharmaceuticals Ltd undervalued or overvalued?

Is Balaxi Pharmaceuticals Ltd a good buy now?

About Balaxi Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.